%0 Journal Article
%T Clinical Outcomes of Stereotactic Body Radiotherapy for Patients with Lung Tumors in the State of Oligo-Recurrence
%A Tetsuya Inoue
%A Norio Katoh
%A Rikiya Onimaru
%A Hiroki Shirato
%J Pulmonary Medicine
%D 2012
%I Hindawi Publishing Corporation
%R 10.1155/2012/369820
%X We retrospectively evaluated the clinical outcomes of patients with oligometastatic lung tumors who underwent stereotactic body radiotherapy (SBRT). Twenty-two patients with one or two oligometastatic lung tumors were treated with SBRT at our institution between 1999 and 2009. With a median follow-up period of 25 months from the date of SBRT to the detection of oligometastatic lung tumors, the patients' 3- and 5-year overall survival (OS) and progression-free survival (PFS) rates were 72% and 54%, respectively. The median disease-free interval (DFI) between the treatment of the primary site and SBRT to oligometastatic lung tumors was 41 months. The OS of patients with a DFI ¡Ý£¿36 months was significantly longer than that of the patients with a DFI < 36 months by the log-rank test ( ). For patients with a DFI ¡Ý£¿36 months, the 3- and 5-year OS rates were both 88%, compared to 50% for the patients with a DFI <£¿36 months. The primary tumor of all patients was locally controlled when SBRT to oligometastatic lung tumors was performed, and thus they were in the state of ¡°oligo-recurrence.¡± Patients with oligometastatic lung lesions treated by SBRT had good prognoses. This was especially true of the patients with a long DFI and in the state of ¡°oligo-recurrence.¡± 1. Introduction Most patients who have had any recurrent or metastatic sites of cancer are considered to be in their last stage of life. However, new notions of oligometastases and oligo-recurrence have been proposed [1¨C9]. Oligometastases is the state in which the patient shows distant recurrence in only a limited number of regions. The clinical state of oligometastatic disease was proposed in 1995 by Hellman and Weichselbaum [1], who hypothesized that local control of oligometastases may yield improved systemic control and prolonged survival. Niibe et al. also discussed the state of oligo-recurrence [2¨C4]; they defined it as oligometastases with a controlled primary cancer site. Stereotactic body radiotherapy (SBRT) with a high local dose has been applied to extracranial diseases such as peripheral stage I nonsmall cell lung cancer (NSCLC), and it has been reported to provide excellent local control and survival compatible with surgery [10, 11]. SBRT has also been used in Japan for patients with fewer than three lung metastases ¡Ü5£¿cm in diameter. In the present study, we retrospectively analyzed our experience with SBRT for patients with oligometastatic lung tumors. 2. Methods and Materials 2.1. Patient Characteristics A database of patients who received SBRT for metastatic lung tumors at our
%U http://www.hindawi.com/journals/pm/2012/369820/